Background
Although the incidence of gastric cancer is decreasing annually because of the popularization of Helicobacter pylori detection and eradication and improvements in living conditions, it represents one of the largest disease burdens worldwide [1]. According to the statistics reported by the World Health Organization in 2016, gastric cancer accounts for 1.53% of deaths worldwide, second only to lung cancer [2]. Due to the high H. pylori infection rate, dietary habits, and susceptibility genes, approximately 50% of gastric cancer cases worldwide occur in East Asian populations [3].
Radical gastrectomy, the standard treatment with a curative intent for patients with early-stage gastric cancer, can substantially prolong disease-free and overall survival [4]. However, chronic complications after the surgery and adjuvant chemoradiotherapy, such as chronic gastrointestinal disorders (e.g., abdominal distension and diarrhea) and general symptoms (e.g., physical fatigue and mental issue), are common and may lead to discomfort, malnutrition, hypoimmunity, decreased quality of life, and even cancer relapse [5]. Although the management of chronic complications is crucial for improving the prognosis of patients with gastric cancer, there are no specific interventions in the current guidelines for treating the complications except for surveillance and nutritional support [4, 6, 7]. Therefore, alternative and complementary therapies are popular in clinical practice [8, 9]; in particular, traditional Chinese medicine (TCM) is widely used to treat postgastrectomy complications in China, which has the heaviest disease burden of gastric cancer globally [10–12].
In TCM theory, the spleen (also written as “pi”, an abstract digestive organ in TCM that differs from the Western medical definition of the spleen as an immune organ) is responsible for transporting food and water, and qi is the vital life force produced by vital activity [13]. Patients who have undergone radical gastrectomy and chemoradiotherapy can easily suffer damage to the spleen and qi, leading to a spleen qi deficiency (SQD) syndrome, the typical symptoms of which include stomach and abdominal distension, dyspepsia, chest and stomach distress, borborygmus, diarrhea, fatigue, weakness, and weight loss [11, 14].
Dietary TCM therapy is a healthcare approach that penetrates Chinese people’s daily life. For example, people like eating medlar to tonify the kidney and liver and avoid contraindicated stimulating food (e.g., mutton, cock, and carp) to prevent the progression of inflammation or cancer. However, the efficacy of these dietary therapies is limited by their simple structure. Theoretically, dietary TCM formulas composed of multiple herbs will have a better efficacy than the simple forms.
Shen Ling Bai Zhu San, a classic TCM formula with the effects of invigorating the spleen and replenishing qi, has been validated to be effective and safe in treating SQD syndrome by empirical evidence for more than 3000 years [15]. It consists of Renshen (ginseng), Fuling (tuckahoe), Baizhu (atractylodes), Yiyiren (coixenolide), Shanyao (Chinese yam), Lianzi (lotus seed), Sharen (amomum), Jiegen (Platycodon), Baibiandou (white hyacinth bean), and Gancao (licorice), all of which are herbs that can be eaten as food (i.e., dietary herbs) except for Baizhu. Therefore, Shen Ling Bai Zhu San is appropriate for modification as a dietary TCM formula.
There is some evidence supporting the gastrointestinal protection and regulatory effects of Shen Ling Bai Zhu San. Animal studies have suggested that Shen Ling Bai Zhu San has the effects of regulating gut flora and increasing gastrointestinal motility [16]. A population-based survey from Taiwan showed that the number of Shen Ling Bai Zhu San prescriptions ranked fourth among all TCM formulas among 46,119 patients with gastric cancer and significantly decreased mortality in patients undergoing both total and partial gastrectomy during a 3.56-year median follow-up period [17]. A guideline developed by the Beijing Academy of Traditional Chinese Medicine recommends using Shen Ling Bai Zhu San as an adjuvant therapy for treating gastric cancer based on randomized controlled trial (RCT) evidence [18]. However, all RCTs supporting the efficacy of Shen Ling Bai Zhu San in the guidelines are of low quality.
A currently used dietary TCM formula called Hou Gu Mi Xi (HGMX) was developed by Jiangzhong Pharmaceutical (group) Co., Ltd. (Jiangxi, China), and is modified from Shen Ling Bai Zhu San. To modify the dietary formulation, HGMX does not contain Baizhu, which cannot be taken as a dietary supplement, and instead contains an alternative herb (Jupi) to maintain the main effects. As a result, all the herbs in HGMX can be used as both a drug and a dietary supplement according to the regulations in China. HGMX also increases the proportion of Fuling, Yiyiren, and Baibiandou to improve the effects of tonifying the spleen and dispelling dampness and decreases the proportion of Renshen, Shanyao, Lianzi, and Gancao because these herbs can cause dampness, which may affect the efficacy. The comparative components of HGMX and Shen Ling Bai Zhu San are presented in Table 1. In HGMX, Renshen and Fuling are the principal drugs, with Renshen having the main effects of tonifying qi and reinforcing the spleen and Fuling being responsible for dispelling dampness. Yiyiren, Shanyao, and Lianzi are used as adjuvant drugs to enhance the effects of the principal drugs, and Sharen, Jiegen, Baibiandou, Gancao, and Jupi help with the regulation and utilization of the entire formula. In addition, long-term patient compliance with Shen Ling Bai Zhu San is limited by the powder preparations and poor taste. To improve patient compliance, the HGMX preparation is changed from a powder to oatmeal by adding japonica rice and oats so that it can be brewed as a rice paste and conveniently eaten for breakfast. Japonica rice and oats also have slight effects of tonifying the spleen, which may enhance the efficacy of the herbs in HGMX.
Table 1. Detailed components of Hou Gu Mi Xi and Shen Ling Bai Zhu San
Hou Gu Mi Xi | Shen Ling Bai Zhu San | ||
|---|---|---|---|
Component | Part used | Proportion | Proportion |
Renshen (ginseng) | Root | 5.0% | 12.9% |
Fuling (tuckahoe) | Sclerotium | 20.0% | 12.9% |
Yiyiren (coixenolide) | Seed | 20.0% | 6.5% |
Shanyao (Chinese yam) | Root | 10.0% | 12.9% |
Lianzi (lotus seed) | Fruit | 10.0% | 6.5% |
Sharen (amomum) | Fruit | 1.0% | 6.5% |
Jiegen (Platycodon) | Stem | 5.0% | 6.5% |
Baibiandou (white hyacinth bean) | Seed | 20.0% | 9.7% |
Gancao (licorice) | Stem | 5.0% | 12.9% |
Jupi (orange peel) | Pericarp | 5.0% | Baizhu (atractylodes) 12.9% |
Every 30 g of Hou Gu Mi Xi contains an additional 13 g of early rice and 6.9 g of oats, in addition to 10.1 g of herbs
Based on TCM theory, we hypothesize that HGMX will be beneficial and safe for SQD syndrome caused by radical gastrectomy with better long-term patient compliance. However, because of the modifications, the RCT evidence for Shen Ling Bai Zhu San cannot be directly applied to HGMX, and furthermore, this evidence is not reliable. To evaluate the efficacy and safety of HGMX in patients with SQD and gastric cancer who have undergone radical gastrectomy, we plan to perform a 2-year randomized placebo-controlled trial (RCT). The results of this RCT will provide evidence for HGMX as an alternative and complementary therapy for the long-term management of chronic postgastrectomy complications.
Methods/design
Study design and recruitment
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial. The flowchart of the study is presented in Fig. 1. The reporting of the protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines [19]. Additional file 2 contains the SPIRIT checklist. Four tertiary hospitals have agreed to participate in the trial, namely, the First Affiliated Hospital of Nanchang University, the Second Affiliated Hospital of Nanchang University, Jiangxi Hospital of Traditional Chinese Medicine, and Jiangxi Provincial Cancer Hospital.
Fig. 1 [Images not available. See PDF.]
Flowchart of the study
The trial will recruit participants through Internet advertisements and posters in the hospitals. Patients who have undergone radical gastrectomy for gastric cancer and show interest in participating in the trial will be evaluated by an attending clinician to determine their eligibility. The clinician will inform the patient of the detailed study objectives, the study process, and the potential benefits and risks. All participants will sign an informed consent form prior to participation.
Patient eligibility
An eligible patient should meet all of the following criteria:
Age between 18 and 70 years
Pathological diagnosis of gastric cancer
Underwent radical gastrectomy, radiotherapy, chemotherapy, and treatment of surgical complications (such as leaks, strictures, and marginal ulcers) 2 weeks to 1 year previously
Fair performance status indicated by a score on the Eastern Cooperative Oncology Group (ECOG) questionnaire ≤1.
Signed the informed consent form
Diagnosed with SQD syndrome based on TCM theory as follows:
- [NEST]
Primary symptoms of spleen deficiency: (1) poor appetite, (2) stomach or abdominal distention, and (3) abnormal stools (loose stools or diarrhea)
Primary symptoms of qi deficiency: (1) physical fatigue and weakness and (2) mental fatigue and taciturnity
Secondary symptoms: (1) loss of taste or hypodipsia, (2) stomach or abdominal pain, (3) stomach tightness, (4) nausea or vomiting, (5) abnormal bowel sounds, (6) leanness or puffiness, (7) sallow complexion, (8) powerless defecation, and (9) facial or limb edema
Auxiliary symptoms: pale, swollen, or scalloped tongue with a thin and white coating.
Patients who meet two primary symptoms of spleen deficiency plus two primary symptoms of qi deficiency, two primary symptoms of spleen deficiency plus one primary symptom of qi deficiency plus one auxiliary symptom, or one primary symptom of spleen deficiency plus one primary symptom of qi deficiency plus two secondary symptoms plus one auxiliary symptom will be diagnosed with SQD syndrome.
An eligible patient should not meet any of the following exclusion criteria:
Stage IV gastric cancer according to the Japanese classification criteria [20]
Completed radical gastrectomy, radiotherapy, and chemotherapy more than 1 year previously
Impaired liver function (total bilirubin > 2 × upper limit of normal (ULN), alanine transaminase > 2 × ULN, or aspartate aminotransferase > 2 × ULN), kidney function (serum creatinine > 2 × ULN), or hematopoiesis (neutrophil count < 0.5 × 109/L, thrombocyte count < 20 × 109/L, or absolute reticulocyte count < 15 × 109/L)
Obviously abnormal electrocardiogram
Severe mental disorder
Other severe diseases (e.g., multiple organ failure or acquired immune deficiency syndrome)
Pregnant or breastfeeding
Allergy to the test sample
Unwilling to provide personal information.
Randomization and blinding
Eligible patients will be randomly assigned at a 1:1 ratio to receive either HGMX or placebo. We generated the random sequence using computer software. An independent randomization management center is responsible for sequentially assigning the random number and distributing trial samples to patients to ensure that the process of allocation is concealed. Clinicians, patients, data collectors, and outcome assessors will be blinded to the group assignment. The allocation will be unblinded if a severe adverse event occurs and when the final data analysis is complete.
Interventions and concomitant treatments
Eligible patients will receive either 30 g/day HGMX or 30 g/day placebo taken orally for 2 years. Every 30 g of HGMX contains 10.1 g of herbal materials. The placebo consists of early rice and oats and is identical to HGMX in terms of preparation, packaging, labeling, and color but is slightly different in taste and smell; according to our simulation test, the two treatments should be impossible to distinguish. The test samples will be distributed to patients once per month. Other Chinese herbal medicines and Western drugs to treat gastrointestinal symptoms (e.g., proton pump inhibitors, prokinetics) are prohibited. The patients will be asked to sign an integrity commitment; they should truthfully report whether they used a treatment outside the regimen at any time. This information will be recorded and used for sensitivity analyses.
Both groups will undergo surveillance of gastric cancer according to the Japanese Gastric Cancer Treatment Guidelines 2014 [4] and continuous concomitant care for other comorbidities (such as hypertension, diabetes mellitus, and osteoarthritis) during the study follow-up period. Concomitant treatments will be recorded at each visit.
Outcome measurements
Primary outcome
The primary outcome is the change in the total score of the Spleen Qi Deficiency Symptoms Grading and Quantifying scale (SQD scale). The SQD scale is a modified version of the classic scale for assessing the degree of SQD in the Clinical Guideline of New Drugs for Traditional Chinese Medicine [21]. The SQD scale consists of 17 items regarding symptoms of SQD: (1) stomach distension, (2) abdominal distension, (3) physical fatigue and weakness, (4) mental fatigue and taciturnity, (5) loss of appetite, (6) abnormal stools, (7) stomach pain, (8) stomach tightness, (9) abdominal pain, (10) acid reflux, (11) belching, (12) nausea and vomiting, (13) abnormal bowel sounds, (14) powerless defecation, (15) sallow complexion, (16) loss of taste and hypodipsia, and (17) facial and limb edema. Items 1–6 are the main symptoms; the other items are secondary symptoms. The items are assessed for duration (0–3 points, only available for items 1–2 and 7–9), severity (0–3 points, not available for item 13), frequency per day (0–4 points; 0–3 points for item 5), and frequency per week (0–5 points). The total score is the sum of the scores of each item (the main symptoms are scored twice) and ranges from 0 to 292. A higher score indicates a more severe symptom. Compared with the classic scale, we added four items (items 1, 7, 10, and 11), defined the main symptoms according to TCM theory, and assessed each item for duration, severity, and frequency per day and per week rather than only for severity. The details of the SQD scale are presented in Additional file 1.
Secondary outcomes
The secondary outcomes are:
Quality of life, assessed by a change in the Short Form 36 scale score [22]
Performance status, assessed by a change in the ECOG questionnaire score [23]
Changes from baseline in body weight and body mass index
Progression-free survival, assessed by pathological examination, computed tomography, and/or magnetic resonance imaging.
Safety outcomes
The safety outcomes are as follows:
Adverse events (AEs), such as abnormal results (greater or less than 2 × normal reference interval) in routine blood, urine, and stool tests; liver function tests (alanine transaminase, aspartate aminotransferase, total bilirubin, direct bilirubin, and indirect bilirubin); kidney function tests (serum creatinine and urea nitrogen); coagulation function (prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen); or electrocardiograms; as well as any other new-onset symptoms or diseases related or unrelated to the intervention
Severe AEs (SAEs) are those AEs that lead to new or prolonged hospitalization, disability, admission to the intensive care unit, mortal danger, or death. SAEs will be reported to the principal investigator, the ethics committee of the hospital, and the Jiangxi Food and Drug Administration within 24 h
Withdrawal due to AEs.
Other assessments
Demographic profiles and histories of patients will be recorded at the baseline visit, including sex, age, marital status, education level, smoking and drinking habits, comorbidities, pathological type of gastric cancer, gastric cancer stage, type of resection surgery, chemoradiotherapy regimen, and medication history for the past 3 months.
Study visits and outcome assessments
The duration of follow-up will be 2 years. Patients will visit at baseline and at 2, 4, 8, 26, 52, 78, and 104 weeks. At each visit, questionnaires and physical examinations will be completed, self-reported AEs will be recorded, and compliance will be assessed. At 8, 26, 52, 78, and 104 weeks, laboratory examinations and electrocardiograms will be performed, and cancer progression will be assessed. A detailed schedule of the trial is presented in Fig. 2.
Fig. 2 [Images not available. See PDF.]
Schedule of the trial process. Abbreviations: ALT alanine transaminase, AST aspartate aminotransferase, TBIL total bilirubin, DBIL direct bilirubin, IBIL indirect bilirubin, SCr serum creatinine, BUN blood urea nitrogen, PT prothrombin time, APTT activated partial thromboplastin time, TT thrombin time, FIB fibrinogen
Sample size estimation
This RCT is a superiority trial, and an appropriate formula was used to estimate sample size [24]. Based on the results of our preliminary observational study and expert advice, we assume an α of 0.05, a 1 –β of 0.80, a between-group difference in primary outcome (total SQD scale score) δ of 8.0, a pooled standard deviation of 14.5, and an allowable dropout rate of 20%. The total sample size is expected to be 130 (65 in each group).
Statistical analysis
Data analysis will be performed with Stata v14.0 (StataCorp LLC, College Station, TX, USA). The main primary outcome analysis will be based on the intention-to-treat data set, where the missing values will not be imputed and the patients who took unscheduled medications will be kept in their original group. We will also perform four sets of sensitivity analyses to test the robustness of the results of the main analyses, including (1) using the per protocol data set; (2) imputing missing data using various methods dependent on the proportion and distribution of the missing data; (3) excluding patients who become aware of the grouping accidentally during the trial, which also aims to estimate the placebo effects; and (4) excluding patients who took unscheduled medications. The analysis of secondary outcomes will be based on the per protocol data set, and the analysis of safety outcomes will be based on the safety data set only, both with no imputation. Interim data analyses will be performed after weeks 8 and 52.
Descriptive analysis will be conducted to explore the means and standard deviations of the continuous variables. We will assess the treatment effects by comparing the mean between-group differences of the continuous endpoints with a normal distribution using the independent t test. The skewed continuous variables will be described using medians and interquartile ranges. We will use the Mann-Whitney U test to assess the equivalency of the skewed continuous variable distributions. Moreover, we will describe categorical variables through their frequencies and percentages. We will evaluate the between-group differences using Pearson’s chi-square test for the cases with expected counts greater than 5 in more than 20% of cells and greater than 1 in any cell or Fisher’s exact test otherwise. We will perform subgroup analyses stratified by gastric cancer stage and chemoradiotherapy regimen for the primary outcome. We set α = 0.05 as the nominal type I error rate, which will be adjusted for the multiple t test using the O’Brien-Fleming group sequential method [25].
Data collection and monitoring
All investigators involved in the trial will receive research training based on standard operating procedures. An independent data monitoring committee (DMC) at Jiangxi University of Traditional Chinese Medicine will be founded and be responsible for supervising the entire trial process. Data collection, such as questionnaire surveys, physical examinations, biological samples, and laboratory examinations, will be performed by qualified physicians at each research center. Student volunteers, as clinical research coordinators, from Jiangxi University of Traditional Chinese Medicine will be in charge of contacting patients for timely follow-up. Each research hospital will have a clinical research associate from the Jiangxi University of Traditional Chinese Medicine who will be in charge of monitoring patient compliance and case report form completeness and will address issues during the trial. The original case report forms will be inputted into the online database by two clinical research coordinators in duplicate. Personal information for all patients will be anonymized. The database will be password protected and will be managed by the DMC. An independent analyst will have access to the database only during the data analysis period. The DMC will also have the authority to discontinue the entire trial according to the following standards: (1) HGMX does not show any efficacy toward SQD symptoms up to 8 weeks of follow-up, as indicated by an absolute difference < 5 on the SQD scale score between the two groups (this difference is estimated based on the unpublished results of our other trial assessing HGMX for nonorganic gastrointestinal disorders); (2) HGMX does not show statistically significant efficacy for any outcome up to 52 weeks of follow-up compared with placebo; and (3) any severe AE related to HGMX occurs.
Compliance and withdrawal
To improve patient compliance, we will offer all test samples (HGMX and placebo) and scheduled examinations free of charge, and patients will receive a travel allowance of 100 yuan at each visit. At the recruitment stage, researchers will emphasize the length of the 2-year treatment and follow-up to patients who are willing to join the trial. The patients will be allowed to complete each follow-up within ±3 days of the scheduled date for the weeks 2, 4, and 8 visits and within ±7 days for the weeks 26, 52, 78, and 104 visits. The used packaging bags will be reclaimed to check patients’ compliance.
Patients will be withdrawn from the trial for the following reasons:
Cancer progression and restarting of radiotherapy or chemotherapy
Recurrence of surgical complications
Continuous deterioration of SQD symptoms
Poor compliance, indicated by the use of less than 80% of the prescribed trial drug or more than two missed visits
Active withdrawal. Patients can actively withdraw from the trial at any time for any reason, and subsequent treatment will not be affected
Discussion
Some previous RCTs assessed the effects of Shen Ling Bai Zhu San, the basic formula of HGMX, for treating patients with gastric cancer. These RCTs showed promising results, such as reduction in the incidence and severity of postoperative ileus, irritable bowel syndrome, and anemia [26], remission of gastrointestinal symptoms [27], and improvement in quality of life [28], which could also support the efficacy of HGMX to some degree. However, all of these RCTs had a short treatment course (≤ 8 weeks) and were at high risk of selection and performance bias due to a lack of reporting of information regarding allocation concealment, blindness, and data monitoring. Therefore, high-quality RCT evidence is warranted regarding the efficacy of HGMX for patients who have undergone radical gastrectomy for gastric cancer.
This RCT aims to clarify whether HGMX, as a dietary formula based on TCM theory, is effective and safe for improving SQD syndrome, quality of life, performance status, and prognosis of patients with gastric cancer who have undergone radical gastrectomy. To improve the quality of study reporting and conduct, we will develop a standard operating procedure manual according to the principles of the Consolidated Standards of Reporting Trials Extension for Chinese Herbal Medicine Formulas [29] and will thoroughly train all investigators. A potential limitation of this trial is that we will use a modified version of the classic SQD scale that has not been validated (no reliability or validity evaluation).
Based on our pilot observations, many patients undergoing gastrectomy achieved quick remission of their gastrointestinal symptoms with 8 weeks of HGMX treatment. Thus, we decided to use three visits (at weeks 2, 4, and 8) to validate the short-term effects of HGMX, which will also provide data for the early discontinuation of the trial as determined by the DMC. The aim of the visits on weeks 26, 52, 78, and 104 will be to investigate the long-term efficacy and safety of HGMX. To improve long-term patient compliance—the key point for obtaining precise results in this trial—we will only include patients with an ECOG score ≤ 1, which ensures that they have sufficient physical abilities to complete this long-term trial and their gastrointestinal symptoms are mild and tolerable so that the need for additional medicine is infrequent. If this trial proves the efficacy of HGMX in patients with good physical performance, we will consider conducting further trials that focus on patients who have worse physical performance (e.g., ECOG score ≥ 2). Moreover, based on our experience, most patients with gastric cancer will return to the hospital to receive regular postoperative follow-up with their attending physicians. Therefore, we anticipate that good compliance with the protocol can be ensured for most patients during the 2-year follow-up period.
This RCT is one of a series of RCTs (the other two trials will focus on nonorganic gastrointestinal disorders and peptic ulcer diseases) assessing the capacity of HGMX to improve gastrointestinal function and systemic symptoms. Although dietary TCM formulas are widely used in clinical practice in China, RCTs with a rigorous design and long-term follow-up are still lacking. To the best of our knowledge, this RCT will be the first to assess a dietary TCM formula for the management of gastric cancer. The results of the RCTs will provide experience and evidence for developing guidelines and policies for facilitating the reasonable use of dietary TCM formulas.
Trial status
The protocol version number is 3.2. Trial recruitment was started on May 22, 2017, and the trial has enrolled 80 patients at the time of manuscript submission. Recruitment is expected to be completed in October 2019.
Acknowledgements
We wish to thank a statistician, Fei Jiang from Hong Kong University, for her constructive advice on the statistical plan and the student volunteers from Jiangxi University of Traditional Chinese Medicine (Yihang Zhong, Xiaoqing Wu, Daoshi Lian, Zhifu Wu, Zhuanlai Chen, Lingfeng Wan, and Dongying Zou) for their great efforts in enrollment of persons in the study.
Dissemination policy
Study findings will be shared with participants, healthcare providers, and policymakers through research reports, conference presentations, and the Internet. The results will also be disseminated through publication in peer-reviewed journals.
Authors’ contributions
XZ and DMY designed the study and drafted the manuscript; WFZ, WJL, and SX provided methodological advice and critically revised the manuscript; HYN, YPJ, KHZ, YF, YYW, XYY, and HL were involved with recruitment and follow-up; XFC and XS conceived and designed the study, developed the statistical analysis plan, reviewed the manuscript, and act as the guarantors. All authors have read and approved the final version of the manuscript.
Funding
This work is supported by a Health and Family Planning Commission of Jiangxi Province project (No. 2016B028), the “1050” Young Talents Scientific Project of Jiangxi University of Traditional Chinese Medicine (no. 207/1141900102), and Jiangzhong Pharmaceutical (group) Co., Ltd. (No. 2016918). The company will provide test samples of HGMX and placebo but will not play any role in study design, conduct, data management, data analysis, or publication.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
This study has been approved by the ethics committees in Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine (No. JZFYLL2016093010), First Affiliated Hospital of Nanchang University (No. 2016047), Second Affiliated Hospital of Nanchang University (No. 2016YYLS10), and Jiangxi Provincial Cancer Hospital (No. 2016013-KY011). The trial will be conducted in compliance with the Declaration of Helsinki and the principles of Good Clinical Practice. The protocol was registered at ClinicalTrials.gov (NCT03025152) on January 17, 2017. Written informed consent will be obtained from all volunteers, and the study will conform to the ethical principles set forth by the Declaration of Helsinki.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Abbreviations
Adverse event
Data monitoring committee
Eastern Cooperative Oncology Group
Hou Gu Mi Xi
Randomized controlled trial
Severe adverse event
Standard Protocol Items: Recommendations for Interventional Trials
Spleen Qi Deficiency Symptoms Grading and Quantifying scale
Spleen qi deficiency
Traditional Chinese medicine
Upper limit of normal
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
1. Ang, TL; Fock, KM. Clinical epidemiology of gastric cancer. Singap Med J; 2014; 55,
2. Rahman, R; Asombang, AW; Ibdah, JA. Characteristics of gastric cancer in Asia. World J Gastroenterol; 2014; 20,
3. World Health Organization. World Health Statistics 2018. 2018. http://www.who.int/gho/publications/world_health_statistics/2018/en/. Accessed 12 June 2018.
4. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer; 2017; 20, pp. 1):1-1)19. [DOI: https://dx.doi.org/10.1007/s10120-016-0622-4]
5. Li, ZY; Shan, F; Zhang, LH et al. Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World J Surg Oncol; 2011; 9, 110. [DOI: https://dx.doi.org/10.1186/1477-7819-9-110] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21942969][PubMedCentral: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204253]
6. De Manzoni, G; Marrelli, D; Baiocchi, GL et al. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer; 2017; 20,
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gastric Cancer Version 2.2018. 2018. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 21 July 2018.
8. Takiguchi, S; Hiura, Y; Takahashi, T et al. Effect of rikkunshito, a Japanese herbal medicine, on gastrointestinal symptoms and ghrelin levels in gastric cancer patients after gastrectomy. Gastric Cancer; 2013; 16,
9. Yoshikawa, K; Shimada, M; Wakabayashi, G et al. Effect of daikenchuto, a traditional Japanese herbal medicine, after total gastrectomy for gastric cancer: a multicenter, randomized, double-blind, placebo-controlled, phase II trial. J Am Coll Surg; 2015; 221,
10. Hsiung, WT; Chang, YC; Yeh, ML et al. Acupressure improves the postoperative comfort of gastric cancer patients: a randomised controlled trial. Complement Ther Med; 2015; 23,
11. Yang, L; Li, TT; Chu, YT et al. Traditional Chinese medical comprehensive therapy for cancer-related fatigue. Chin J Integr Med; 2016; 22,
12. Zilberstein, B; Abbud Ferreira, J; Cecconello, I. Management of postoperative complications in gastric cancer. Minerva Gastroenterol Dietol; 2011; 57,
13. Lin HY, Zhao YP, Xu GP, et al. Weaker cognitive control abilities of Pi (Spleen) qi-deficient individuals supported Chinese medicine diagnosis. Chin J Integr Med. 2017. https://doi.org/10.1007/s11655-017-2967-x.
14. Wang, F; Xia, Y; Li, D et al. Clinic observation on TCM syndrome evolvement of postoperative gastric carcinoma. Chin Arch Tradit Chin Med; 2010; 28,
15. Tai Ping Hui Min He Ji Ju. Tai Ping Hui Min He Ji Ju Fang. Juan 3 (Imperial Grace Formulary of the Tai Ping Era, Volume 3). Beijing: People's Medical Publishing House; 2017.
16. Ding, W; Zhou, B; Zhai, M et al. Influence of Shenlinbaizhu Powder in enteric bacteria flora in mouse model with spleen-insufficiency syndrome. J Beijing Univ Tradit Chin Med; 2006; 29,
17. Hung, KF; Hsu, CP; Chiang, JH et al. Complementary Chinese herbal medicine therapy improves survival of patients with gastric cancer in Taiwan: a nationwide retrospective matched-cohort study. J Ethnopharmacol; 2017; 199, pp. 168-174. [DOI: https://dx.doi.org/10.1016/j.jep.2017.02.004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28163114]
18. Beijing Academy of Traditional Chinese Medicine. Expert consensus on clinical application of Shen Ling Bai Zhu San and Bu Zhong Yi Qi prescription. Beijing J Tradit Chin Med; 2018; 37,
19. Chan, AW; Tetzlaff, JM; Altman, DG et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med; 2013; 158,
20. Sano, T; Aiko, T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer; 2011; 14,
21. Zheng, X. Clinical guideline of new drugs for traditional Chinese medicine; 1993; Beijing, Medicine Science and Technology Press of China:
22. Ware, JE, Jr; Sherbourne, CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care; 1992; 30,
23. Oken, MM; Creech, RH; Tormey, DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol; 1982; 5,
24. Zhong, B. How to calculate sample size in randomized controlled trial?. J Thorac Dis; 2009; 1,
25. Jennison, C; Turnbull, BW. Group sequential methods with applications to clinical trials; 1999; Abingdon, Chapman & Hall/CRC:
26. Chen, Y. Effects of Shen Ling Bai Zhu San on common postoperative complications of gastric cancer. Guide China Med; 2016; 14,
27. Yang, Z. Study on recovery of gastric function after total gastrectomy and jejunectomy under treatments of Shen Ling Bai Zhu San; 2016; Guangzhou, Guangzhou University of Traditional Chinsese Medicine (academic dissertation):
28. Li, Y. Effect of large-dose Shen Ling Bai Zhu San on postoperative chemotherapy tolerance and quality of life in patients with gastric cancer. Guangming J Chin Med; 2017; 32,
29. Cheng, CW; Wu, TX; Shang, HC et al. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med; 2017; 167,
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© The Author(s). 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Background
Spleen qi deficiency (SQD), a syndrome based on traditional Chinese medicine (TCM) theory, is common in patients after radical gastrectomy. SQD manifests with chronic gastrointestinal disorders and systemic symptoms and is challenging to manage. Hou Gu Mi Xi (HGMX) is a dietary TCM formula for SQD. This study aims to evaluate the efficacy and safety of HGMX in patients with SQD who have undergone radical gastrectomy for gastric cancer.
Methods and design
This study is a multicenter, randomized, double-blind, placebo-controlled trial. One hundred thirty patients with SQD who have undergone radical gastrectomy for gastric cancer will be assigned to receive either HGMX or placebo for 2 years. The main outcome will be changes in SQD symptoms assessed by the Spleen Qi Deficiency Symptoms Grading and Quantifying Scale. The secondary outcomes will be changes in quality of life assessed by the Short Form 36 scale, performance status as assessed by the Eastern Cooperative Oncology Group Performance Status scale, body weight, and body mass index. Progression-free survival will also be assessed as a secondary outcome. Adverse events (AEs), severe AEs, and study withdrawal due to AEs will be recorded to evaluate the safety of HGMX.
Discussion
The results of this trial will provide initial evidence for the use of HGMX as an alternative and complementary intervention to manage chronic postoperative complications in patients who have undergone radical gastrectomy for gastric cancer.
Trial registration
ClinicalTrials.gov, NCT03025152. Registered on 17 January 2017.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Jiangxi University of Traditional Chinese Medicine, Evidence-based Medicine Research Center, School of Basic Medical Sciences, Nanchang, China (GRID:grid.411868.2) (ISNI:0000 0004 1798 0690)
2 Inner Mongolia Agricultural University, School of Food Science and Engineering, Inner Mongolia, China (GRID:grid.411638.9) (ISNI:0000 0004 1756 9607)
3 Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Department of Spleen, Stomach, Liver and Gallbladder Diseases, Jiangxi, China (GRID:grid.478032.a)
4 First Affiliated Hospital of Nanchang University, Department of Gastroenterology, Jiangxi, China (GRID:grid.478032.a)
5 Second Affiliated Hospital of Nanchang University, Department of Traditional Chinese Medicine, Jiangxi, China (GRID:grid.478032.a)
6 Jiangxi Provincial Cancer Hospital, Third Department of Oncology, Jiangxi, China (GRID:grid.452533.6) (ISNI:0000 0004 1763 3891)
7 Jiangxi University of Traditional Chinese Medicine, Evidence-based Medicine Research Center, School of Basic Medical Sciences, Nanchang, China (GRID:grid.411868.2) (ISNI:0000 0004 1798 0690); West China Hospital, Sichuan University, Chinese Evidence-based Medicine Center, Sichuan, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)